Home/ Stocks/ OKUR

OnKure Therapeutics, Inc. Class A Common Stock

OKUR XNAS

$3.91 -0.26 (-6.57%) ▼ 15-min delayed

Open

$3.92

High

$3.97

Low

$3.85

Volume

89.6K

Market Cap

$157.95M

About OnKure Therapeutics, Inc. Class A Common Stock

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 45 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$458.0K	$-15,157,000	$-1.11
FY 2025	$3.43M	$-59,517,000	$-4.40
Q3 2025	$802.0K	$-14,699,000	$-1.09
Q2 2025	$934.0K	$-15,390,000	$-1.14

Related Market News

No specific coverage for OKUR yet. Check out our latest market news or earnings calendar.

Get OKUR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on OnKure Therapeutics, Inc. Class A Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.